DIAGNOSIS OF ALZHEIMER DISEASE STAGE BY MONONUCLEAR CELL CYTOKINE SECRETIONS

Abstract: A method of diagnosing and determining the disease stage of a degenerative disease of the central nervous system associated with the impairment of integrative brain function is disclosed. The method includes the steps of: (a) measuring a cytokine production level of peripheral mononuclear cells from a peripheral blood sample and (b) determining the disease stage by comparing the level determined in step (a) with a level generated by age-matched normal controls.

Description: DIAGNOSIS OF ALZHEIMER DISEASE STAGE BY MONONUCLEAR CELL CYTOKINE SECRETIONS TECHNICAL FIELD The present invention relates to objective methods of diagnosing the disease stage of Alzheimer's disease. BACKGROUND OF THE INVENTION Alzheimer's disease (AD), the onset of which occurs mainly in the later years of life, is a neurodegenerative disease causing progressive dementia. In AD, neuropathologic examination of the brain reveals in most patients the presence of neuritic plaques, abnormal neurites, and neurofibrillary tangles containing paired helical filaments composed of cross-linked poly- peptides that are especially prominent in the cerebral cortex and hippocampal formation. The mechanism of progression of the disease is unknown. The phenotype heterogeneity of the disease makes diagnosis difficult and definite diagnoses can be made only after detection of characteristic pathological changes such as neurofibrilla tangles and neuritic plaques. 1 Different etiologies have been attributed to AD, one of which has a possible immunological basis. 15 The role of the immune system in the pathogenesis of Alzheimer's disease has been widely researched, 20 ' 25,27 but the exact role of the immune system has not been clearly established. The fact that immune functions change with age is also well documented. 16 ' 30 ' 34,40 Published reports indicate a number of discrepancies concerning immunological indices associated with AD, 27 including several studies on cytokine secretion by mononuclear cells of AD patients as compared to age-matched controls, 4 ' 29,36 and cytokine serum levels in patients with AD. 8,10 These studies suggest that immune interactions exist between the central nervous system and peripheral blood lymphocytes of AD patients. Since AD is no longer viewed today as a single unified clinical condition, but as a complex syndrome, 14 it has been postulated that the presence of different clinical subgroups may imply a differential involvement of the immune system. 23 ' 24 ' 35 U.S. patent 4,728,605 to Fudenberg et al. further teaches the association of the immune system in the pathogenesis of AD, the teachings of which are incorporated herein by reference. The presence of cytokines and their receptors in the brain, as well as the endogenous synthesis of cytokines, such as IL-1, IL-3 and IL-6, has been documented. 7 ' 9,18 ' 32 The physiological functions of these cytokines are virtually unknown. However, in light of the view that there is an active and highly-regulated communication between the brain and the immune system, 6,28 and as cytokines are known to function via a cascade effect, applicants postulate a link between the cytokine profile in the blood stream and that in the brain which, in turn, may have a bearing on the appearance of neurological diseases and subsequent disease progression. There are many forms of dementia presenting with symptoms similar to AD. Many of these other conditions are treatable, such as brain tumors, thyroid and other endocrine dysfunctions, depression, infection, vitamin and mineral deficiencies, metabolic disorders, unrecognized injuries and medication side effects. AD is not treatable and so diagnosis is critical. In general, AD is diagnosed using behavioral symptoms and psychological scoring which involve subjective judgements. U.S. patents 4,728,605, 4,886,743, 5,015,570, 5,017,470, 5,100,645, and 5,231,001 present objective methods of diagnosing AD. However, none of the above methods determine the stage or progression of the disease, i.e., the severity of the disease. Specifically, none of the above-listed patents, or studies show any correlation between impaired cytokine production in AD and the disease stage of the patient. The determination of disease progression is still dependent on the behavioral symptoms and psychological scoring which involve subjective judgements. Currently, the only existing FDA-approved drug for Alzheimer's is tacrine hydrochloride (Cognex™, Warner- Lambert) which is very expensive, has extensive side effects, and has been shown to be effective only in the mild stages of the disease. Therefore, an objective method of diagnosing AD at the early stages would be useful in eliciting maximal effect from this drug. SUMMARY OF THE INVENTION AND ADVANTAGES According to the present invention, a method of diagnosing and determining the disease stage or severity of a degenerative disease of the central nervous system (CNS) associated with the impairment of integrative brain function is disclosed. The method includes the steps of: (a) measuring a cytokine production level of peripheral mononuclear cells from a peripheral blood sample and (b) determining the disease stage by comparing the level determined in step (a) with a level generated by age- matched normal controls, thereby providing a cytokine profile for each patient. It has been determined that increases or decreases of specific cytokine production over controls reflect disease and, more particularly, the disease stage. The present invention provides an objective diagnosis and measurement of the stages of these degenerative diseases of the CNS and can provide critical information useful for treatment of the patient. The Alzheimer type of dementia is one degenerative disease of the CNS with which the present invention can be practiced. BRIEF DESCRIPTION OF THE DRAWINGS Other advantages of the present invention will be readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings wherein: FIGURE IA is a histogram showing levels of IL-2 produced by PHA-activated mononuclear cells in AD mild and moderately-severe patients and healthy age-matched controls; FIGURE IB is a graph showing levels of IL-2 produced by PHA-activated mononuclear cells over time in AD mild and moderately-severe patients and healthy age-matched controls; FIGURE 1C is a histogram showing levels of IL-2 produced by PHA-activated mononuclear cells and measured by a bioassay in AD mild and moderately-severe patients, MID patients and healthy age-matched controls; FIGURE ID is a histogram showing levels of IL-2 produced by PHA-activated mononuclear cells and measured by an ELISA in AD mild and moderately-severe patients, MID patients and healthy age-matched controls; FIGURE 2 is a histogram showing levels of IFN-γ production by T-helper cells in groups as listed in FIGURE IA; FIGURE 3 is a histogram showing levels of IL-3-LA production by mononuclear cells in groups as listed in FIGURE IA; FIGURE 4 is a histogram showing levels of TNF-c. production in LPS-activated monocytes cells, measured by ELISA, in AD mild and moderately-severe patients, MID patients, healthy age-matched controls and healthy young subjects; FIGURE 5A is a histogram showing levels of IL-lβ production by activated monocytes in groups as listed in Figure IA; FIGURE 5B is a histogram showing levels of IL-lβ production by activated macrocytes in AD mild and moderately-severe patients, MID patients, healthy age- matched controls and healthy young subjects,- and FIGURE 6 is a histogram showing levels of IL-6 production by PHA-activated mononuclear cells in groups as listed in Figure IA. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT The present invention provides a method of objectively determining a patient's disease stage, or disease severity, of a degenerative disease of the central nervous system (CNS) associated with the impairment of integrative brain function. The Alzheimer type of dementia is one degenerative disease of the CNS with which the present invention can be practiced. The patient's blood is drawn and mononuclear cells (MNC) are isolated and, where appropriate, monocytes were separated by plating 5xl0 6 MNC per well in 24-well culture plates for 1 hour at 37°C and 7.5% C0 2 , followed by removal of nonadherent cells. The cells are then cultured and the media analyzed for the presence of cytokines released by the cells. Similarly, the levels in healthy age-matched controls (OC) are also determined. The assays can be either bioassays, ELISAs or RIAs. Various cytokines can be assayed and the culture conditions varied to allow production of the cytokine of interest. For example, mitogens, such as PHA and LPS, can be added to the media during the culture period to cause the production of IL-2 and IFN-α or TNF-γ and IL-lβ, respectively, as described hereinbelow. In the final step of the present invention, the cytokine levels of the AD patient are compared to those of the OC control, providing a cytokine profile of each patient tested. It has been determined that increases of IL-2, TNF-α, IFN-γ, and IL-6 production over controls indicates a moderately-severe disease stage, while a decrease of IL-3-LA levels and an increase of IL-6 levels from control levels indicates a mild disease stage. The present invention provides an objective measurement of the stages of these degenerative diseases of the CNS. In the present invention, cytokine secretion in AD patients in the mild and moderately severe stage of the disease was evaluated. This is the first comparative method utilizing cytokine secretion by MNC of AD patients correlated with the patients' clinical condition. The present invention focuses on immune changes associated with AD, independent of changes in the normal aging population. Several studies on cytokine production of AD patients have been reported. ' 8,10,29 ' 36 The results obtained when testing cytokine secretion in AD patients before clinical subdivision were in line with those of Miller et al. 30 and Bessler et al. 4 who report no differences in IFN-γ, IL-lβ, and 11-2 production levels by mononuclear cells between AD patients and their age-matched controls. However, in the present invention, when the patients were divided into the mild and moderately severe groups, a different cytokine profile emerged. A significant decrease in IL-3-LA and increase in IL-6 production levels in the mild AD group as compared to OC was observed. In the moderately-severe AD group, there was a significant increase in IL-2, IFN-γ, IL-6, and TNF-α production as compared to OC and IL-3-LA levels were higher (though not significantly) than those of the mild group, approaching control levels. Increased cytosolic-free calcium levels in lymphocytes of AD have been reported. 2 This finding supports the observation herein of increased IL-2 secretion, for calcium is pivotal as a transmembrane messenger in the activation signal for T lymphocytes and in eliciting transcription of the IL-2 gene. 31 The relationship between increased production of IL-2 and IFN-γ can be understood in light of the fact that the lymphokine IL-2 is one of the interferon inducers. 33 These findings may imply the presence of augmented TH1 clones (secretors of IL-2 and IFN-γ) in the moderately severe stage of the disease. TH1 subsets have been shown to provide B cell help for IgM, IgG, and IgA synthesis known to be elevated in the more advanced stages of AD disease. 22 To conclude, the results show a correlation between production levels of IL-2, IFN-γ, TNF-α, IL-3-LA, and IL-6 by mononuclear cells (MNC) of Alzheimer patients and the clinical condition of these patients. These results indicate that immunologically defined substages of AD may serve as diagnostic markers in the progression of the disease. Immunological changes occurring in patients with AD have not been sufficiently clarified or defined so far. These results show for the first time that changes occurring in patients with mild AD are not expressed in patients with moderately-severe AD (i.e. decrease in IL-3- LA) . Furthermore, the cytokine profile observed in moderately-severe patients was not seen in mild AD patients. A kit providing the appropriate reagents to measure IL-2, IFN-γ, TNF-α, IL-3-LA, and IL-6, as well as the appropriate age-matched control samples, can be made with the present invention. By providing the age-matched controls, standardization of the assay and interpretation of results can be obtained. The above discussion provides a factual basis for the use of cytokines as an objective determination of the disease stage of cognitive disorders such as AD. The methods used with and the utility of the present invention can be shown by the following examples. EXAMPLES Subjects and Methods: Subjects: Thirty-six patients, 22 females and 14 males, with senile dementia of the Alzheimer type (mean age 76.6±3 years), and 30 age and sex-matched controls (mean age 74±2.2 years) were studied. All the patients were living in their homes and attended the same day-care unit. Age-matched elderly controls (OC) consisted of healthy elderly subjects without cognitive impairment according to the Record on Independent Living (RIL) criteria. 39 An additional control group of 10 patients diagnosed as severe multiple infarct dementia (MID) according to the Hachinski et al. 19 criteria, was included in several of the experiments. All participants were free of any medication or diseases known to affect lymphocyte function and two blood samples were drawn from each participant within a two-week interval to exclude possibility of intercurrent infection which may affect the immune system. Clinical diagnosis and intellectual performance tests. Diagnosis of AD patients was based on NINCDS-ADRDA criteria. 26 Biochemical and metabolic parameters such as total blood count, blood chemistry, B12, Folic acid and VDRL and thyroid function tests were evaluated. Patients were also monitored by electroencephalogram (EEG) and computed tomography (CT) brain scanning. Severity of dementia was assessed in AD patients using the RIL criteria. Patients were divided into two subgroups: mild dementia (score 17-32) and moderately- severe dementia (score 33-64) . The mild dementia group consisted of 17 patients, 10 females and 7 males (mean age 75.8+3.1 years); and the moderately-severe dementia group consisted of 19 patients, 12 females and 7 males (mean age 77.4+2.9 years) . The minimum Mental State (MMS) test 13 was performed to confirm the level of impairment of each subgroup; mild AD patients group score (16.85±3.86) was significantly higher than those of the moderately-severe patients (6.2±1.39). Cell isolation. Human mononuclear cells (MNC) were separated from fresh heparinized blood of healthy donors and AD patients by Ficoll-Hypaque density gradient centrifugation (Pharmacia, Fine Chemicals, Uppsala, Sweden) as described by Boyum. 5 IL-2 production and quantification. Human MNC, 1.5xl0 6 /ml, were suspended in enriched RPMI-1640 (Gibco) culture medium supplemented with 10% Fetal Calf Serum (FCS) , 2mM L-glutamine, lOmM nonessential amino acids, 3mM sodium pyruvate, 5xl0 ~5 2-mercaptoethanol (2-ME) , and incubated at 37°C in the presence of 10 or 0.5μg/ml phytohemagglutanin (PHA-M; Gibco) for 48 hours. In addition, kinetic studies wherein cells were incubated for 24, 48, and 72 hours were carried out on five samples from each group. Supernatants were collected and assayed for IL-2 activity. 17 The ability of the supernatant fraction to support, the growth of the IL-2-dependent CTLL clone was used to assay IL-2 production (bioassay) . CTLL cells (10 4 per well) were seeded in triplicate in culture medium, with or without dilutions of the supernatant fractions. After 48 hours, [ 3 H] thymidine uptake was determined in a liquid scintillation counter. One unit of IL-2 activity was defined as the reciprocal log 2 dilution required to give 50% of the maximal proliferation of 10 4 IL-2 dependent murine CTLL after 48 hours of culture. A commercially 5. available ELISA test (Advanced Magnetics, USA) was also used for quantification of human IL-2 in the supernatant fraction. IL-3-LA production and assay. Human IL-3-LA was tested in a bioassay as described by Fishman et al. 11 This 0 human growth factor is spontaneously produced by monocytes and lymphocytes. Human MNC cells, 3xl0 6 /ml, were suspended in RPMI-1640 supplemented with 10% FCS and incubated for 48 hours at 37°C. Supernatants were collected and IL-3-LA activity was assayed by its ability to stimulate the 5 proliferation of the IL-3 responsive cell line 32D-cl23. Briefly, 0.1 ml of 32D-cl23 cells (10 4 per well) were seeded in triplicate in culture medium with or without dilution of the supernatant fraction. Cultures were incubated for 24 hours at 37°C. Each well was pulsed with lμCi [ 3 H]thymidine 0 for the final six hours of culture. Thymidine uptake was determined in a liquid scintillation counter. One unit of 11-3-LA activity was defined as the reciprocal log 2 dilution required to give 50% of the maximum proliferation of 10 4 32D-cl23 cells after 48 hours of culture. The 5 standard was recombinant murine IL-3 (Genzyme, Boston, MA) . TNF-cy secretion and bioassay. Human monocyte cultures were obtained by adhering 5xl0 6 MNC to 24 well tissue culture plates for 1 hour at 37°C, followed by removal of nonadherent cells. The resulting onolayers were reconstituted with enriched RPMI medium and cultured with LPS (Sigma, lOμg/ml) for 6 hours. The TNF-α content in supernatants thus obtained was evaluated using a commercially available ELISA kit (Advanced Magnetics, USA) . Alternatively, TNF-α could be measured by a cell cytotoxicity assay. 12 IL-6 secretion and quantification. Secretion of IL-6 was obtained under culture conditions previously described for production of IL-2. The IL-6 content in supernatant fractions was measured using a commercially available ELISA kit from Advanced Magnetics, USA. IFN-γ secretion and bioassay. IFN-γ levels were tested in supernatants prepared by the same method as that for human IL-2. Supernatants were assayed by a commercially available ELISA kit (T-Cell Sciences, Cambridge, MA) . IL-lβ secretion and quantification. For the production of IL-lβ, 5xl0 6 /ml MNC were suspended in enriched RPMI and incubated for one hour at 37°C. Nonadherent cells were thereafter washed out of the tissue culture plate and the remaining adherent cells were cultured in enriched RPMI-1640 supplemented with lOμg/ml lipopolysaccharide (LPS, Sigma) for six hours. Supernatants were assessed by a commercially available ELISA kit (Cistrom Biotechnology, Pine Brook NJ) . Statistical Analysis. Mean values were compared by the (nonparametric) Wilcoxon test. Results Cytokine production levels were measured in age- matched elderly controls and AD patients subdivided into mild and moderately-severe groups. Table 1 shows patient characteristics compared to healthy controls. Table 1: study Group Characteristics A D' - i'd AD * modPratelv-severe control Number of patients 1 7 1 9 30 Gender (M/F) 7/ 1 0 7/ 1 2 1 2/ 1 8 Age (years)b 75.8±3.1 77.4±2.9 74±2.2 Mini-mental scoreb 16.85.5±3.85 - 6.2±1.39 29.5±0.78 * AD, Alzheimer's disease b - values are mean±SD Example 1: Levels of IL-2 Production by PHA- Activated Mononuclear Cells. Levels of IL-2 production by PHA activated (lOμg/ml) MNC after 48 hours of incubation are shown in Figure IA. There was a significant increase in IL-2 levels secreted by MNC of moderately-severe AD patients as compared to the other two groups (37.1±6 U/ml vs. 17.49±4.2 U/ml (mild), and 19±4.1 U/ml (OC) (p<0.01; p<0.01) . No significant difference was observed in IL-2 secretion between mild AD patients and OC. Similar results were obtained when MNC were incubated with a sub-optimal dose of PHA (0.5μg/ml): moderately severe levels (24±2.3 U/ml) vs. mild levels (6.1±2.9 U/ml) and control levels (13.2±4.7 U/ml), p<0.02. Kinetic studies were subsequently performed on five samples from each experimental group. As can be seen in Figure IB, IL-2 levels of production in the moderately-severe group were significantly higher at all time points (p<0.01) as compared to both mild and OC groups. IL-2 production levels in the mild group were slightly lower though non-significant compared to the control group. In a second experiment, MID patients (average age 76.6 +49 years) were included. As can be seen in Figure 1C, levels of IL-2 secretion in MID patients, as measured by bioassay, are significantly higher than that of healthy elderly control subjects and mild AD patients (p>0.01). The MID results do not differ significantly from moderately-severe patients. These results suggest that elevated IL-2 levels may reflect the degree of severity of dementia rather than specificity of dementia. In a third experiment, IL-2 secretion as measured by ELISA was determined in healthy elderly control subjects, MID patients, and AD mild and moderately-severe patients. As seen in Figure ID, the results parallel those seen with the bioassay. IL-2 secretion is a marker of moderately-severe dementia patents. Example 2: Levels of IFN-γ Production by T-Helper Cells. The production levels of IFN-γ were assayed. IFN-γ is also secreted by T-helper cells and augmented by the presence of IL-2. Results similar to those of IL-2 were obtained for IFN-γ levels when tested in supernatants from PHA optimally-stimulated MNC incubated for 48 hours. As may be seen in Figure 2, the levels of IFN-γ secretion of moderately-severe AD patients were significantly higher when compared to OC (342±119 U/ml patients vs. 11.75+37.8 U/ml, p<0.05), and higher, though not significantly, than in the mild group. No differences were observed between mild AD patients and OC. Example 3 : Levels of IL-3-LA Production by Mononuclear Cells. The cytokine and IL-3-LA is secreted both by macrophages and lymphocytes. IL-3-LA has been found to be endogenously synthesized in the brain and, therefore, it was of interest to test levels of production by MNC in varying stages of AD. Figure 3 summarizes the levels of spontaneous IL-3-LA secretion in supernatants from MNC cells incubated for 48 hours. As may be seen, a significant decrease in IL-3-LA levels was observed in mild AD patients compared to OC (44.4±0.94 U/ml vs. 35.43±3.25 U/ml, p=p.01) . Results indicated a small, though not significant, increase in the moderately-severe groups as compared to the mild group, suggesting a return to control levels. Example 4: Levels of TNF-α Production by LPS- Activated Monocytes. TNF-α levels were measured in AD mild and moderately-severe patients, MID patients, healthy age- matched controls and healthy young subjects utilizing an ELISA kit. As can be seen in Figure 4, a significant increase (p<0.01) in TNF-α production was found in the moderately-severe group as compared to other experimental groups. Example 5: Levels of IL-lβ Production by Activated Macrophages. Levels of IL-lβ secretion were determined. IL-lβ is a monokine secreted by activated macrophages and found to be secreted in the central nervous system. No differences in IL-lβ production levels were observed when age-matched healthy controls were compared to AD patients (Figure 5A) . In a second experiment, a second control group consisting of ten MID patients (mean age 76.6±4.9) was also evaluated, as well as healthy young subjects (mean age 46.8±4.9 years). As seen in Figure 5B, no significant differences were found between the age-matched controls, MID patients, and the AD patients. Example 6: Levels of IL-6 Production by PHA- Activated Mononuclear Cells. Recent studies 3,19 ' 37 have proposed the concept of an interleukin-6 (IL-6) mediated-cerebral acute phase response as an element of Alzheimer's disease (AD) pathophysiology. This concept stems from the fact that amyloid in the senile plaques is tightly associated with acute-phase proteins which are known to be mediated by interleukin-6. Increase serum levels of acute-phase proteins have been reported in AD; 21 however, serum levels of IL-6 were not found to be elevated in AD. As can be seen in Figure 6, a significant increase in IL-6 production was seen both in the mild and moderately severe groups as compared to elderly controls (mild: 2136±311 pg/ml; moderately severe: 1750+144 pg/ml vs. OC: 1209±166 pg/ml, p<0.01). These results indicated that IL-6 secretion by mononuclear cells can serve as a marker for AD; and, in particular, indicate different stages of the disease. In addition to the elderly age and sex-matched controls, a second control group consisting of severely demented patients, i.e., multiple infarct dementia patients (MID) were included. In these studies, IL-6 levels in MID patients (1393±174 pg/ml) were not significantly different from that of elderly controls (1209±166 pg/ml) and were significantly increased compared to the mild (2136±311 pg/ml) and moderately severe (1750±144 pg/ml) AD groups (p<0.02) . In summary, cytokine secretion by human mononuclear cells (MNC) was investigated in age-matched controls and in patients with Alzheimer's disease (AD) . AD patients were divided into two study groups: "mild" and "moderately-severe" based on psychosocial testing. A significant increase in interleukin-2 (IL-2) , gamma interferon (IFN-γ) , tumor necrosis factor-α (TNF-α) , and interleukin-6 (IL-6) secretion was found in AD patients in the moderately-severe stage of the disease; whereas, in the mild stage of the disease, there was a significant decrease in interleukin-3 (IL-3-LA) like activity and increase in IL-6 activity. No significant differences were found in the level of production of interleukin-lβ (IL-lβ) . These results demonstrate the existence of defective immune functions in AD patients which are correlated with the disease stage of these patients and can be used to objectively diagnose disease and determine the disease stage. The determination of the disease stage can be used to determine which treatment would be most effective. The invention has been described in an illustrative manner, and it is to be understood that the terminology which has been used is intended to be in the nature of words of description rather than of limitation. Obviously, many modifications and variations of the present invention are possible in light of the above teachings. It is, therefore, to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described. REFERENCES 1. Adams and Victor (1989) "Alzheimer Disease", in Prin . of Neur. , McGraw Hill Inf. Services, NY, pp. 923-929. 2. Adunsky et al. (1991) "Increased cytosolic free calcium in lymphocytes of Alzheimer patients", J. Neuroiπimunol . 33:167-172. 3. Bauer et al. (1992) "The participation of interleukin-6 in the pathogenesis of Alzheimer's disease", Res . in Immunol . 143:650-657. 4. Bessler et al. (1989) "Lymphokine production in patients with Alzheimer disease", Agre and Ageing, 18:21-25. 5. Boyum (1968) "Separation of leukocytes from blood and bone marrow", Scand. J. Clin . Lab. Invest . Vol. 21 (suppl. 97), 31-50. 6. Cserr and Knopf (1992) "Cervical lymphatics, the blood brain barrier and immunoreactivty of the brain: a new view", lirimunol. Today 13:507-511. 7. Cunningham and DeSouza (1993) "Interleukin 1 receptors in the brain and endocrine tissues", Immunol . Today 14:171-176. 8. Esumi et al. (1991) "Serum interleukin-2 levels in patients with dementia of Alzheimer type", Acta . Neurol . Scand. 84:65-67. 9. Farrar et al. (1987) "The immune logical brain", Immunol . Rev. 100:361-378 10. Fillit et al. (1991) "Elevated circulating tumor necrosis factor in Alzheimer's disease", Neurosci . Lett . 129:318-320. 11. Fishman et al. (1990) "Recent advances in interluekin-3 research: A review", Israel J. Med. Sci . 26:414-419. 12. Flick and Gifford (1984) "Comparison of in vi tro cell cytotoxic assays for tumor necrosis factor", Journal Immunol . Methods 68:167-175. 13. Folstein et al. (1975) "Mini mental state: a practical method for grading cognitive state of patients for clinician", J. Psych. Res . 12:189-198. 14. Fudenberg and Singh (1988) "Alzheimer's 'syndrome': Prognosis of subsets with different etiology and preliminary effects of immunotherapy", Drug Dev. Res . 15:165-174. 15. Gautrin and Gauthier (1989) "Alzheimer's disease: environmental factors and etiologic hypotheses", Can . J. Neurol . Sci . 16:375-387. 16. Geokas et al. (1990) "The aging process", Ann. Intern. Med. 113:455-466. 17. Gillis et al. (1978) "T cell growth factor: parameters of production and quantitative microassay for activity", J. Immunol . 120:2027-2032. 18. Griffin et al. (1989) "Brain interleukin 1 and S-100 immunoreactivity are elevated in Down Syndrome/Alzheimer disease", PNAS USA 86:7611-7615. 19. Hachinski et al. (1974) "Multifarct dementia, a course of mental deterioration in the elderly", Lancet ii:207-208 20. Hulette and Walford (1987) "Immunological aspects of Alzheimer disease: a review", Alzh . Dis . Assoc. Disord. 1:72-82. 21. Ikeda et al. (1991) "Interleukin-2 receptor in peripheral blood lymphocytes of Alzheimer's disease patients", Acta . Psychiatr. Scand. 84:262-265. 22. Kalter and Kelly (1975) "Alzheimer's disease: evaluation of immunologic indices", NY State J. Med. 75:1222-1225. 23. Licastro et al. (1990) "Zinc and thymic hormone-dependent immunity in normal ageing...", J. Neuroimmunol . 27:201-208. 24. Mayeux et al. (1985) "Heterogeneity in dementia of Alz. type: evidence of subgroups", Neurology 35:453-454. 25. McGeer et al. (1991) "Reactions of immune system in chronic degenerative neurological diseases", Can . J. Neur. Sci . 18:371-379. 26. McKann et al. (1984) "Clinical diagnosis of Alzheimer's disease" (Report of NINCDS-ADRDA Work Group) Neurology 34:939-949. 27. McRae and Dahlstrom (1992) "Immune responses in brains of Alzheimer and Parkinson's disease patients..", Rev. Neuroscience 3:79-97. 28. Merrill (1990) "Interleukin-2 effect in central nervous system", NY Acad. Sci . 594:188-199. 29. Miller et al. (1981) "Immunological studies in senile dementia of Alz. type.- evid. for enhanced suppressor cell activity", Ann. Neurol . 10:506-510. 30. Miller (1989) "Minireview: The cell biology of aging: immun. models", J. Gerontol . 44:B4-B8. 31. Mills et al. (1985) "Increase in cytosolic free calcium concen. is an intracellular message for prod, of interleukin 2...", J. Immunol 134:1640-1649. 32. Namba et al. (1990) "Reactive microglias are positive for interleukin-2 and interleukin-6 in Alz. dementia brain", J. Clin . Exp. Med. 152:785-786. 33. Ortaldo et al. (1987) "Effects of natural and recombinant IL-2 on reg. of γlFN production and natural killer activity...", J. Immunol . 133:779-783. 34. Rogers and Rovigatti (1988) "Immunologic and tissue culture approaches to neurobiology of aging", JVeuro-iol. Aging 9:759-762. 35. Roth (1986) "The Association of clinical and neurological findings and bearing on class and etiology of Alz. disease", Br. Med. Bull . 42:42-50. 36. Skias et al. (1985) "Senile dementia of Alz. type (SDAT) : Red. T8+ cell-mediated supp. activity", Neurology 35:1635-1638. 37. Vandenabeele et al. (1991) "Is amyloidogenesis during Alzheimer's disease due to IL- l/IL-6 mediated 'acute phase response' in brain?" Imm . Today 12:217-219. 39. Weintraub et al. (1982) "Daily living activities in assess, of dementia", in Alzheimer's disease : report of progress in research, Raven Press, NY, pp. 109-192. 40. Zats and Goldstein (1985) "Thymosins, lymphokines and immunology of aging", Gerontology 31:263- 277.

Claims: CLAIMS What is claimed is : l. A method of diagnosing and determining a stage of a degenerative disease of the central nervous system associated with the impairment of integrative brain function by (a) measuring a cytokine production level of peripheral mononuclear cells from a blood sample, (b) determining a stage of a degenerative disease of the central nervous system associated with the impairment of integrative brain function by comparing the level determined in said step (a) with a level generated by age-matched normal controls . 2. The method of claim 1 wherein the disease determined is a dementia of the Alzheimer's type. 3. The method of claim 1 wherein the cytokine production measured is for interleukin-2 (IL-2) . 4. The method of claim 1 wherein the cytokine production measured is for gamma interferon (IFN-γ) . 5. The method of claim 1 wherein the cytokine production measured is for interleukin-6 (IL-6) . 6. The method of claim 1 wherein the cytokine production measured is for tumor necrosis factor α (TNF-α) . 7. The method of claim 1 wherein the cytokine production measured is for interleukin-3 like activity (IL-3-LA) . 8. A method of diagnosing a moderately- severe stage of Alzheimer's disease (AD) by (a) measuring a cytokine production level of peripheral mononuclear cells, (b) determining a moderate-severe stage by comparing the level determined in said step (a) with a level generated by age-matched normal controls and finding the patient levels increased over the controls . 9. The method of claim 8 wherein the cytokine production measured is for interleukin-6 (IL-6) 10. The method of claim 8 wherein the cytokine production measured is for interleukin-2 (IL-2) . 11. The method of claim 8 wherein the cytokine production measured is for gamma interferon (IFN-γ) . 12. The method of claim 8 wherein the cytokine production measured is for tumor necrosis factor α (TNF-o.) . 13. A method of diagnosing a mild stage of Alzheimer's disease by (a) measuring IL-3-LA and IL-6 cytokine production levels of peripheral mononuclear cells from a blood sample; and (b) determining a mild stage by comparing the level determined in said step (a) with a level generated by age-matched normal controls and finding the patient levels of IL-3-LA decreased from the controls and IL-6 production levels increased over the controls. 14. A method of determining treatment for a degenerative disease of the central nervous system associated with the impairment of integrative brain function by (a) measuring a cytokine production level of peripheral mononuclear cells; (b) determining a stage of a degenerative disease of the central nervous system associated with the impairment of integrative brain function by comparing the level determined in said step (a) with a level generated by age-matched normal controls, thereby providing a profile of cytokine production for the patient, and (c) administering a treatment determined by the cytokine profile. 15. The method of claim 14 wherein the treatment is the administration of tacrine hydrochloride. 16. The method of claim 14 wherein the disease is a dementia of the Alzheimer's type. 17. The method of claim 14 wherein the cytokine production measured is for interleukin-2 (IL-2) . 18. The method of claim 14 wherein the cytokine production measured is for gamma interferon (IFN-γ) . 19. The method of claim 14 wherein the cytokine production measured is for tumor necrosis factor α (TNF-o.) . 20. The method of claim 14 wherein the cytokine production measured is for interleukin-3 like activity (IL-3-LA) . 21. A kit for determining diagnosis and disease stage of Alzheimer's disease said kit including means for measuring production of IL-3-LA, IL-6, TNF-cϋ, IFN-γ, and IL-2 by peripheral mononuclear cells and standardized age-matched control samples.

Inventors: HUBERMAN MOSHE, SHALIT FRANCES, SREDNI BENJAMIN, HUBERMAN, MOSHE, SHALIT, FRANCES, SREDNI, BENJAMIN
Applicants: MOR RESEARCH APPLIC LTD, SHALIT FRANCES, UNIV BAR ILAN, BAR-ILAN UNIVERSITY, MOR RESEARCH APPLICATIONS LTD., SHALIT, FRANCES
Application year: 1995
Main classification: G01N33
IPC codes: G01N33